These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11353837)

  • 1. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.
    Marzio G; Verhoef K; Vink M; Berkhout B
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6342-7. PubMed ID: 11353837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.
    Berkhout B; Verhoef K; Marzio G; Klaver B; Vink M; Zhou X; Das AT
    J Neurovirol; 2002 Dec; 8 Suppl 2():134-7. PubMed ID: 12491165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control.
    Zhou X; Vink M; Berkhout B; Das AT
    Retrovirology; 2006 Nov; 3():82. PubMed ID: 17094796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
    Das AT; Zhou X; Vink M; Klaver B; Berkhout B
    Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.
    Verhoef K; Marzio G; Hillen W; Bujard H; Berkhout B
    J Virol; 2001 Jan; 75(2):979-87. PubMed ID: 11134311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.
    Das AT; Klaver B; Harwig A; Vink M; Ooms M; Centlivre M; Berkhout B
    J Virol; 2007 Oct; 81(20):11159-69. PubMed ID: 17670816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the Tet-On system for regulated gene expression through viral evolution.
    Zhou X; Vink M; Klaver B; Berkhout B; Das AT
    Gene Ther; 2006 Oct; 13(19):1382-90. PubMed ID: 16724096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
    Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
    Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry.
    Das AT; Baldwin CE; Vink M; Berkhout B
    J Virol; 2005 Mar; 79(6):3855-8. PubMed ID: 15731280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A conditionally replicating virus as a novel approach toward an HIV vaccine.
    Das AT; Verhoef K; Berkhout B
    Methods Enzymol; 2004; 388():359-79. PubMed ID: 15289083
    [No Abstract]   [Full Text] [Related]  

  • 12. Dox-dependent SIVmac with tetracycline-inducible promoter in the U3 promoter region.
    Xiao Y; Kuwata T; Miura T; Hayami M; Shida H
    Virology; 2000 Apr; 269(2):268-75. PubMed ID: 10753705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution.
    Das AT; Klaver B; Centlivre M; Harwig A; Ooms M; Page M; Almond N; Yuan F; Piatak M; Lifson JD; Berkhout B
    Retrovirology; 2008 Jun; 5():44. PubMed ID: 18533993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
    Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
    Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication.
    Westerhout EM; Vink M; Haasnoot PC; Das AT; Berkhout B
    Mol Ther; 2006 Aug; 14(2):268-75. PubMed ID: 16697708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus evolution as a tool to study HIV-1 biology.
    Berkhout B; Das AT
    Methods Mol Biol; 2009; 485():436-51. PubMed ID: 19020843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control over HIV-1 replication by an antibiotic; a novel vaccination strategy with a drug-dependent virus.
    Berkhout B; Marzio G; Verhoef K
    Virus Res; 2002 Jan; 82(1-2):103-8. PubMed ID: 11885936
    [No Abstract]   [Full Text] [Related]  

  • 18. The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop.
    Xu W; Morrow CD
    Virology; 2006 Sep; 352(2):380-9. PubMed ID: 16781756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering attenuated virus vaccines by controlling replication fidelity.
    Vignuzzi M; Wendt E; Andino R
    Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
    Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
    J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.